Drug Trial Radar · NCT06581575
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
467
Actual
Start
Oct 16, 2024
Primary completion
Feb 19, 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Immorna Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Conditions
- Herpes Zoster (HZ)
- Infectious Diseases
- Shingles
Interventions
JCXH-105Biological
IM injection
ShingrixBiological
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAE FrequencyTime frame: Day 1 - Day 241 (Week 34)
- Solicited local reaction frequencyTime frame: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
- Solicited systemic reaction frequencyTime frame: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
- AE FrequencyTime frame: Day 1 - Day 241 (Week 34)
- AESIs FrequencyTime frame: Day 1 - Day 241 (Week 34)
- Medically Attended AE FrequencyTime frame: Day 1 - Day 241 (Week 34)
- Immune-Mediated Adverse Events of Special Interest FrequencyTime frame: Day 1 - Day 241 (Week 34)
- gE-Specific CD4+ T cell Response RateTime frame: Day 1 - Day 89 (Week 13)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Noble Clinical Research
Tucson, Arizona
Long Beach Research Institute
Long Beach, California
DM Clinical Research - Chicago
Chicago, Illinois
Quality Clinical Research
Omaha, Nebraska
DM Clinical Research - New Jersey
Jersey City, New Jersey
Delricht Research
Charleston, South Carolina
Delricht Research
Prosper, Texas
DM Clinical Research - Sugarland
Sugar Land, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.